Congenital adrenal hyperplasia: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
'''This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on [[21-hydroxylase deficiency]], [[17 alpha-hydroxylase deficiency]], [[11β-hydroxylase deficiency]], 3-beta-hydroxysteroid dehydrogenase, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia, cholesterol side-chain cleavage enzyme deficiency'''
'''This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on [[21-hydroxylase deficiency]], [[17 alpha-hydroxylase deficiency]], [[11β-hydroxylase deficiency]], 3-beta-hydroxysteroid dehydrogenase deficiency, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia, cholesterol side-chain cleavage enzyme deficiency'''
.
.


Line 10: Line 10:


==Overview==
==Overview==
Congenital adrenal hyperplasia (CAH) refers to any of several autosomal recessive conditions resulting from biochemical paths of the steroidogenesis of cortisol from cholesterol by the adrenal glands. Most of these conditions involve greater or lesser production of sex steroids and can alter development of primary or secondary sex characteristics in affected infants, children, and adults. Only a small minority of people with CAH can be said to have an intersex condition, but this attracted American public attention in the late 1990s and many accounts of varying accuracy have appeared in the popular media. Approximately 95% of cases of CAH are due to 21-hydroxylase deficiency.
 
Prenatal diagnosis can be made in both of these disorders by chorionic villous sampling, but this can only be done at 8-10 weeks. In order to prevent the deleterious effect of excess androgens on genital (and brain!) development, therapy must be started earlier. This is most often considered if there is an affected sibling. Treatment is dexamethasone, which is not degraded by the placenta, but is associated with significant maternal weight gain, hypertension, and edema.
 


==Classification==
==Classification==
Line 28: Line 28:
!Increased
!Increased
!Decreased
!Decreased
!K levels
!Potassium levels
!
!
|-
|-
Line 50: Line 50:
* [[Aldosterone]]
* [[Aldosterone]]
|
|
* High in salt wasting type
* High in salt-wasting type
* Normal in non salt wasting
* Normal in non-salt wasting
|
|
* CYP21A1 and CYP21A2 gene
* CYP21A1 and CYP21A2 gene
Line 59: Line 59:
* Normal
* Normal
|
|
* Female: virilization after puberty
* Female: [[virilization]] after [[puberty]]
* Male: normal appearance
* Male: normal appearance
|
|
Line 66: Line 66:
response to [[ACTH]]  
response to [[ACTH]]  
|
|
* Cortisol
* [[Cortisol]]


* Aldosterone
* [[Aldosterone]]
|
|
* Normal
* Normal
Line 75: Line 75:
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|
* Hypertension
* [[Hypertension]]
|
|
* Female: normal
* Female: normal
* Male: ambiguous  
* Male: [[ambiguous genitalia]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|
* [[Deoxycorticosterone]]
* [[Deoxycorticosterone]]
* [[Corticosterone]]
* [[Corticosterone]]
Line 89: Line 89:
|
|
* Low
* Low
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|  
* CYP17A1
* CYP17A1
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|  
* Hypertension
* [[Hypertension]]
|
|
* Female: ambiguous
* Female: [[ambiguous genitalia]]


* Male: normal or scrotal pigmentation and large phallus
* Male: normal or scrotal pigmentation and large phallus
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|  
* [[Deoxycorticosterone]]
* [[Deoxycorticosterone]]
* 11-Deoxy-[[cortisol]]
* 11-Deoxy-[[cortisol]]
Line 113: Line 113:
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[3 beta-hydroxysteroid dehydrogenase deficiency]]
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[3 beta-hydroxysteroid dehydrogenase deficiency]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|
* Hypotension
* [[Hypotension]]
|Both male and female: ambiguous genitalia
|
* Both male and female: [[ambiguous genitalia]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |
* [[Dehydroepiandrosterone]]
* [[Dehydroepiandrosterone]]
Line 213: Line 214:
* Minimal [[body hair]]
* Minimal [[body hair]]
|-
|-
|-Hydroxysteroid Dehydrogenase
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
|
|
* [[Dehydroepiandrosterone]]
* [[Dehydroepiandrosterone]]
Line 270: Line 271:
* [[Virilization]]
* [[Virilization]]
|-
|-
|-Hydroxysteroid Dehydrogenase
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
|Increased:
|Increased:
* [[DHEA]]
* [[DHEA]]
Line 358: Line 359:
* [[Undervirilization]] in 46,XY individuals due to a block in [[testosterone]] biosynthesis.
* [[Undervirilization]] in 46,XY individuals due to a block in [[testosterone]] biosynthesis.
* Mild [[virilization]] in 46,XX individuals
* Mild [[virilization]] in 46,XX individuals
|Yes in [[female]]
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|Yes in [[female]]
Yes in [[female]]
|Low
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|Normal
Yes in [[female]]
|Normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
Low
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
Normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
Normal
|[[XY]] and [[XX]]
|[[XY]] and [[XX]]
|-
|-
Line 375: Line 381:
* Absence of secondary [[sexual characteristics]]
* Absence of secondary [[sexual characteristics]]
* Minimal [[body hair]]
* Minimal [[body hair]]
|No
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|No
No
|Low
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|Normal
No
|Normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|[[XY]]
Low
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
Normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
Normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
[[XY]]
|-
|-
|[[Gonadal dysgenesis]]
|[[Gonadal dysgenesis]]
Line 390: Line 402:
* [[Streak gonads]]
* [[Streak gonads]]
* [[karyotyping ]]
* [[karyotyping ]]
|Yes
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|Yes
Yes
|Low
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|High
Yes
|High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|[[XY]]
Low
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
[[XY]]
|-
|-
|[[Testicular regression syndrome]]
|[[Testicular regression syndrome]]
Line 402: Line 420:
|
|
* Female phenotype with atrophic [[Mullerian ducts]].
* Female phenotype with atrophic [[Mullerian ducts]].
|No
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|No
No
|Low
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|High
No
|High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|[[XY]]
Low
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
[[XY]]
|-
|-
|[[LH receptor|LH receptor defects]]
|[[LH receptor|LH receptor defects]]
Line 419: Line 443:
** Unresponsiveness to [[hCG]]  
** Unresponsiveness to [[hCG]]  
** Normal levels of [[testosterone]] precursors (produced in the [[adrenal glands]]).
** Normal levels of [[testosterone]] precursors (produced in the [[adrenal glands]]).
|No
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|No
No
|Low
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|High
No
|High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|[[XY]]
Low
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
[[XY]]
|-
|-
|[[5-alpha-reductase deficiency|5-alpha-reductase type 2 deficiency]]
|[[5-alpha-reductase deficiency|5-alpha-reductase type 2 deficiency]]
Line 436: Line 466:
* Defective conversion of [[testosterone]] to [[DHT]].  
* Defective conversion of [[testosterone]] to [[DHT]].  
* [[Testosterone]]:[[DHT]] ratio is >10:1
* [[Testosterone]]:[[DHT]] ratio is >10:1
|No
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|No
No
|Normal male range
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|High to normal
No
|High to normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|[[XY]]
Normal male range
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
High to normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
High to normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
[[XY]]
|-
|-
|[[Androgen insensitivity syndrome]] 
|[[Androgen insensitivity syndrome]] 
Line 449: Line 485:
* Female [[external genitalia]]
* Female [[external genitalia]]
* Resistant to [[testosterone]]
* Resistant to [[testosterone]]
|No
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|Yes
No
|Normal male range
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|Normal
Yes
|Normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
Normal male range
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
Normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
Normal
|[[XY]]
|[[XY]]
|-
|-
Line 462: Line 503:
* Normal female [[genitalia]]
* Normal female [[genitalia]]
* Normal [[breast]] development
* Normal [[breast]] development
|No
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|Yes
No
|Normal [[female]] range
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|Normal
Yes
|Normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|[[XX]]
Normal [[female]] range
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
Normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
Normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
[[XX]]
|-
|-
|[[Ovarian insufficiency|Primary ovarian insufficiency]]
|[[Ovarian insufficiency|Primary ovarian insufficiency]]
Line 474: Line 521:
|
|
* Normal [[female genitalia]]
* Normal [[female genitalia]]
|Yes
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|Yes
Yes
|Normal female range
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|High
Yes
|High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|[[XX]]
Normal female range
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
[[XX]]
|-
|-
|[[Hypogonadotropic hypogonadism]]
|[[Hypogonadotropic hypogonadism]]
Line 488: Line 541:


* No [[puberty]]
* No [[puberty]]
|Yes
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|No
Yes
|Normal female range
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|Low
No
|Normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|[[XX]]
Normal female range
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
Low
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
Normal
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
[[XX]]
|-
|-
|[[Turner syndrome]]
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
[[Turner syndrome]]
|
|
* Chromosomal
* Chromosomal
|
|
* Female [[external genitalia]]
* Female [[external genitalia]]
|Yes
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|Yes
Yes
|Normal [[female]] range
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
|High
Yes
|High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
Normal [[female]] range
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
High
|align="center" style="padding: 5px 5px; background: #F5F5F5;" |
High
|[[Turner syndrome|45 XO]]
|[[Turner syndrome|45 XO]]
|}
|}

Revision as of 20:46, 9 August 2017

This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on 21-hydroxylase deficiency, 17 alpha-hydroxylase deficiency, 11β-hydroxylase deficiency, 3-beta-hydroxysteroid dehydrogenase deficiency, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia, cholesterol side-chain cleavage enzyme deficiency .

Congenital adrenal hyperplasia main page

Overview

Classification

21-hydroxylase deficiency
11β-hydroxylase deficiency
17 alpha-hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Cytochrome P450-oxidoreductase (POR) deficiency (ORD)
Lipoid congenital adrenal hyperplasia

Differential Diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Synonyms and keywords: Congenital adrenal hyperplasia, CAH, Adrenal hyperplasia

Overview

Classification

Congenital adrenal hyperplasia is classified into seven types based on the genetic causes that lead to hyperplasia and hormonal imbalance. There are three zones of hormonal synthesis in adrenal cortex that are shown below, and impairment of each pathway may lead to a specific subtype of congenital adrenal hyperplasia.

Disease History and symptoms Laboratory findings Defective gene
Blood pressure Genitalia Increased Decreased Potassium levels
21-hydroxylase deficiency Classic type
  • Low in salt-wasting
  • Normal in non-salt-wasting
  • Female: ambiguous
  • Male: normal or scrotal pigmentation and large phallus
  • High in salt-wasting type
  • Normal in non-salt wasting
  • CYP21A1 and CYP21A2 gene
Non-classic type
  • Normal

response to ACTH

  • Normal
  • CYP21A1 and CYP21A2 gene
17-α hydroxylase deficiency
  • Low
  • CYP17A1
11-β hydroxylase deficiency
  • Male: normal or scrotal pigmentation and large phallus
  • Low
  • CYP11B1
3 beta-hydroxysteroid dehydrogenase deficiency
  • High
  • HSD3B2
Cytochrome P450-oxidoreductase (POR) deficiency (ORD)
Congenital lipoid adrenal hyperplasia
Cholesterol side-chain cleavage enzyme deficiency

Differential Diagnosis

Congenital adrenal hyperplasia must be differentiated from diseases that cause ambiguous genitalia:[1][2]

Disease name Laboratory tests Important clinical findings
Increased Decreased
Classic type of 21-hydroxylase deficiency
11-β hydroxylase deficiency
17-α hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Gestational hyperandrogenism

Congenital adrenal hyperplasia must be differentiated from diseases that cause virilization and hirsutism in female:[3][2][4]

Disease name Steroid status Other laboratory Important clinical findings
Non-classic type of 21-hydroxylase deficiency Increased:

response to ACTH

  • No symptoms in infancy and male
11-β hydroxylase deficiency Increased:

Decreased:

3 beta-hydroxysteroid dehydrogenase deficiency Increased:

Decreased:

Polycystic ovary syndrome
Adrenal tumors
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Ovarian virilizing tumor
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Cushing's syndrome
Hyperprolactinemia

Some types of congenital adrenal hyperplasia must be differentiated from diseases with primary amenorrhea and female external genitalia.[5][6][7][8][9][10][11][12]

Disease name Cause Differentiating
Findings Uterus Breast development Testosterone LH FSH Karyotyping
Pregnancy HCG positive
3-beta-hydroxysteroid dehydrogenase type 2 deficiency

Yes in female

Yes in female

Low

Normal

Normal

XY and XX
17-alpha-hydroxylase deficiency

No

No

Low

Normal

Normal

XY

Gonadal dysgenesis
  • Mutations in SRY, FOG2/ZFPM2, and WNT1

Yes

Yes

Low

High

High

XY

Testicular regression syndrome
  • Loss of testicular function and tissue early in development

No

No

Low

High

High

XY

LH receptor defects

No

No

Low

High

High

XY

5-alpha-reductase type 2 deficiency

No

No

Normal male range

High to normal

High to normal

XY

Androgen insensitivity syndrome 

No

Yes

Normal male range

Normal

Normal

XY
Mullerian agenesis

No

Yes

Normal female range

Normal

Normal

XX

Primary ovarian insufficiency

Yes

Yes

Normal female range

High

High

XX

Hypogonadotropic hypogonadism
  • Functional, sellar masses

Yes

No

Normal female range

Low

Normal

XX

Turner syndrome

  • Chromosomal

Yes

Yes

Normal female range

High

High

45 XO

References

  1. Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
  2. 2.0 2.1 White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
  3. Hohl A, Ronsoni MF, Oliveira M (2014). "Hirsutism: diagnosis and treatment". Arq Bras Endocrinol Metabol. 58 (2): 97–107. PMID 24830586. Vancouver style error: initials (help)
  4. Melmed, Shlomo (2016). Williams textbook of endocrinology. Philadelphia, PA: Elsevier. ISBN 978-0323297387.=
  5. Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C (2011). "Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients". J. Clin. Endocrinol. Metab. 96 (2): 296–307. doi:10.1210/jc.2010-1024. PMID 21147889.
  6. Moreira AC, Leal AM, Castro M (1990). "Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency". J. Clin. Endocrinol. Metab. 71 (1): 86–91. doi:10.1210/jcem-71-1-86. PMID 2164530.
  7. Heremans GF, Moolenaar AJ, van Gelderen HH (1976). "Female phenotype in a male child due to 17-alpha-hydroxylase deficiency". Arch. Dis. Child. 51 (9): 721–3. PMC 1546244. PMID 999330.
  8. Biglieri EG (1979). "Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome". J. Steroid Biochem. 11 (1B): 653–7. PMID 226795.
  9. Saenger P (1996). "Turner's syndrome". N. Engl. J. Med. 335 (23): 1749–54. doi:10.1056/NEJM199612053352307. PMID 8929268.
  10. Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R (2015). "Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis". Fertil. Steril. 103 (5): 1297–304. doi:10.1016/j.fertnstert.2015.01.043. PMID 25813279.
  11. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170): 1213–5. PMID 4432067.
  12. Schnitzer JJ, Donahoe PK (2001). "Surgical treatment of congenital adrenal hyperplasia". Endocrinol. Metab. Clin. North Am. 30 (1): 137–54. PMID 11344932.